Press Release

New Survey by Greystone Associates Examines Technology and Therapeutic Factors

(Amherst, NH) – Healthcare practitioners and medical researchers have known that for certain diseases combining drugs can have a synergistic, and sometimes dramatic, effect on therapeutic outcomes. While combining two or more drugs in a single delivery package is already established for certain conditions such as asthma and hormone replacement therapy, promising clinical evidence of the therapeutic potential for administering multiple drugs is creating a growing list of afflictions and conditions that can benefit from multi-drug delivery technology.

“As clinical data reinforces the value of multi-drug protocols for the treatment of refractory conditions such as cancer and HIV, drug developers and pharmaceutical strategists are taking a harder look at technology for delivering two or more drugs in the same dosage form factor at different, and sometimes variable, rate profiles,” explains George Perros, Greystone Managing Director. “The availability of multiple drugs in a single delivery system simplifies administration and improves compliance, further benefiting outcomes.”

While interest in multi-drug delivery systems is growing across several therapeutic applications, an area of significant potential is in therapeutic drug combinations for HIV, a disease where the religious administration of multiple drugs is deemed critical to therapeutic outcomes. Chemotherapeutic ‘cocktails’ for various cancers are also strong candidates for multi-drug delivery technology.

These survey findings are contained in a new and comprehensive report: Multi-Drug Delivery Systems: Emerging Therapeutics and Opportunities The report contains a comprehensive assessment of multi-drug delivery technology, and provides an assessment of current and probably future multi-drug combination products, profiles of market participants, industry data and forecasts, and detailed analysis of regulatory and market factors. Organized and written to be of maximum value to pharmaceutical industry decision makers, delivery technology developers, and industry strategists, the report provides a detailed analysis of the growing potential for multi-drug delivery systems in disease therapeutics.

More information is available at www.greystoneassociates.org .

 About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

Contact:

Mark Smith

Voice: 603-595-4340

Fax: 603-804-0466

marksmith@greystoneassociates.org

www.greystoneassociates.org                                         Source: Greystone Associates

For more information:
http://www.greystoneassociates.org/Multi-drug.htm

Last updated on: 27/08/2010 11:40:18